Abstract Background Although low-grade serous ovarian cancer (LGSC) is rare. case-fatality rates are high as most patients present with advanced disease and current cytotoxic therapies are not overly effective. Recognizing that these cancers may be driven by MAPK pathway activation. MEK inhibitors (MEKi) are being tested in clinical trials. https://parisnaturalfoodes.shop/product-category/sprouted-protein-vanilla/